Lonza to Expand Cytotoxic Manufacturing to Serve Growing Oncology API Market

Lonza currently operates high potency GMP laboratory suites on gram-scale. The investment will add multi-kilogram scale cytotoxic production capacity which enables Lonza to offer clinical and commercial production of cytotoxics – all within one dedicated facility. These enhanced fermentation and chemical capabilities, along with existing bioconjugation expertise, will help Lonza to comprehensively address its customers cytotoxic manufacturing challenges.

“This investment speeds our efforts to establish the Lonza Visp site as a Center of Excellence for High Potency Manufacturing,” said Stefan Stoffel, Head of Lonza’s Chemical Manufacturing Business Unit. “With the anticipated expansion to be completed in the second quarter of 2012, Lonza Visp will offer a fully integrated end-to-end development and manufacturing solution for a wide-range of technologies, including highly active pharmaceutical ingredients (HAPIs), cytotoxics, peptides and antibody drug conjugates (ADCs).”

The new facility will provide the necessary production lines to secure API supply and meet the regulatory requirements of the coming decade with strict focus on safe handling of compounds with low occupational exposure limits (OEL) to ensure employee and environmental safety. Lonza’s investment allows its customers to capitalize on the unique infrastructure of the Visp site and avoid investment in expertise, assets, and infrastructure required to work with these highly potent products in a highly regulated environment.

Currently, cytotoxic projects are being initiated within Visp’s state-of-the-art GMP laboratory suites. Upon completion of the expansion, Lonza can smoothly transition customer projects for scale-up in the new manufacturing facility.


Medienkontakt:
Lonza Group Ltd Corporate Communications Dominik Werner Tel +41 61 316 8798 Fax +41 61 316 9798 dominik.werner@lonza.com

Editor's note: Image rights belong to the respective publisher.